ArticleHaematologica2016

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Jennifer R Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.